Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Ovarian Neoplasms 32Breast Neoplasms 18Neoplasms 9Triple Negative Breast Neoplasms 8Neoplasm Metastasis 7Sarcoma 6Prostatic Neoplasms 6Fanconi Anemia, Complementation Group D1 6Pancreatic Neoplasms 5Endometrial Neoplasms 5Stomach Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Small Cell Lung Carcinoma 4Recurrence 4Parkinson Disease 4, Autosomal Dominant Lewy Body 4Fallopian Tube Neoplasms 4Colorectal Neoplasms 4Sarcoma, Ewing 2Rhabdomyosarcoma 2Mesothelioma 2Head and Neck Neoplasms 2Glioma 2Glioblastoma 2Central Nervous System Neoplasms 2Carcinoma, Ovarian Epithelial 2Carcinoma, Non-Small-Cell Lung 2Carcinoma 2Advanced Solid Tumours 2Advanced Solid Tumors 2Wilms Tumor 1

Interventions

pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1olaparib 1Topotecan 1SAR125844 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Malignant Solid Tumors × olaparib × Clear all
NCT00516438 2010-12-08

Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Topotecan

AstraZeneca

Phase 1 Completed
48 enrolled
Other solid neoplasm

Malignant Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡